Equities

Zhejiang Shouxiangu Pharmaceutical Co Ltd

603896:SHH

Zhejiang Shouxiangu Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)18.99
  • Today's Change-0.25 / -1.30%
  • Shares traded2.08m
  • 1 Year change-55.38%
  • Beta1.0030
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5761,300808
Total Receivables, Net124146128
Total Inventory15814899
Prepaid expenses211411
Other current assets, total928255--
Total current assets1,8071,8621,045
Property, plant & equipment, net687605523
Goodwill, net------
Intangibles, net3117883
Long term investments289258271
Note receivable - long term------
Other long term assets------
Total assets3,1742,8561,962
LIABILITIES
Accounts payable146144141
Accrued expenses424133
Notes payable/short-term debt3702730
Current portion long-term debt/capital leases124.875.63
Other current liabilities, total161520
Total current liabilities585478199
Total long term debt364429101
Total debt746706107
Deferred income tax3.783.043.98
Minority interest000.38
Other liabilities, total504138
Total liabilities1,003951343
SHAREHOLDERS EQUITY
Common stock202197152
Additional paid-in capital966856900
Retained earnings (accumulated deficit)1,076908691
Treasury stock - common(165)(165)(165)
Unrealized gain (loss)------
Other equity, total9310941
Total equity2,1711,9061,620
Total liabilities & shareholders' equity3,1742,8561,962
Total common shares outstanding197192193
Treasury shares - common primary issue5.245.245.24
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.